EBVALLO
ATA129-EBV-205
Phase 2 small_molecule active
Quick answer
EBVALLO for EBV+ primary imunodeficiency lymphoproliferative disease (LPD), EBV+ post-transplant LPD where standard first line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors, EBV+ associated post-transplant LPD involving the central nervous system (EBV+ CNS PTLD) is a Phase 2 program (small_molecule) at Pierre Fabre Medicament with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pierre Fabre Medicament
- Indication
- EBV+ primary imunodeficiency lymphoproliferative disease (LPD), EBV+ post-transplant LPD where standard first line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors, EBV+ associated post-transplant LPD involving the central nervous system (EBV+ CNS PTLD)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active